ERd Combination Treatment in Newly Diagnosed Multiple Myeloma (ADVANCE 2.0)

The purpose of this study is to determine the effects that Elranatamab in combination with Lenalidomide and Dexamethasone has on participants that have been newly diagnosed with Multiple Myeloma.

Trial Details

NCT ID
NCT06997081
Phase
PHASE2
Sponsor
University of Miami
Status
RECRUITING
Cancer Type
Multiple Myeloma
Interventions
  • Lenalidomide
  • Dexamethasone
  • Elranatamab
Locations (sample)
  • Miami, Florida, United States|25.77427,-80.19366

Key Eligibility Criteria

  • Newly diagnosed patients with histologically confirmed multiple myeloma (MM) based on the IMWG diagnostic criteria and measurable disease within th…
  • Serum monoclonal protein ≥ 1.0 g/dL
  • Urine monoclonal protein ≥ 200 mg/24 hour
  • Involved serum immunoglobulin free light chain ≥ 10 mg/dL AND abnormal kappa/lambda ratio

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →